X4 Pharmaceuticals

X4 Pharmaceuticals is a Massachusetts-based company that develops novel therapeutics for the treatment of cancer and immunodeficiency diseases.

Business Model:

Revenue: $3M

Employees: 51-200

Detailed X4 Pharmaceuticals Information

Geographic Data

X4 Pharmaceuticals headquarters map

Address: 61 North Beacon Street

City: Boston

State: MA

Zip: 02134

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$55M

Raised Total:

$138M

Metrics

3,586,929Website Global Rank

3,779Website Monthly Traffic

Twitter Followers

Description

X4 Pharmaceuticals is a Massachusetts-based company that develops novel therapeutics for the treatment of cancer and immunodeficiency diseases.

Contact Phone:
+18575298300

Contact Email:

X4 Pharmaceuticals went public on 11/17/2017 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
11/17/2017

Ticker Symbol:
XFOR

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
3/2017 Grant $9.3M Bill & Melinda Gates Foundation
1/2015 Seed $735k
8/2015 Series A $37.5M
12/2022 Post-IPO Equity $65M
10/2017 Series B $35M
12/2015 Series A 1 $37.5M Cormorant Asset Management
Cormorant Asset Management
3/2021 Post-IPO Equity $0 Abingworth
Altium Capital
Bain Capital Life Sciences
Driehaus Capital Management
Ikarian Capital
Lincoln Park Capital Fund
Monashee Investment Management
OrbiMed
Sio Capital Management
Abingworth
Altium Capital
Bain Capital Life Sciences
Driehaus Capital Management
Ikarian Capital
Lincoln Park Capital Fund
Monashee Investment Management
OrbiMed
Sio Capital Management
11/2017 Series B 1 $27M Cormorant Asset Management
Cormorant Asset Management
7/2022 Private Placement $55M
6/2022 Post-IPO Equity $0 Acorn Bioventures
AXA Investment Managers
Bain Capital Life Sciences
Hercules Capital
Lumira Ventures
New Enterprise Associates
OrbiMed
Acorn Bioventures
AXA Investment Managers
Bain Capital Life Sciences
Hercules Capital
Lumira Ventures
New Enterprise Associates
OrbiMed
11/2017 Series A 1 - Thynk Capital, LLC.
Thynk Capital, LLC.
1/2014 Seed Round 1 - SV Health Investors
SV Health Investors
6/2022 Post-IPO Equity 7 $55M Acorn Bioventures
AXA Investment Managers
Bain Capital Life Sciences
Hercules Capital
Lumira Ventures
New Enterprise Associates
OrbiMed
Acorn Bioventures
AXA Investment Managers
Bain Capital Life Sciences
Hercules Capital
Lumira Ventures
New Enterprise Associates
OrbiMed
3/2021 Post-IPO Equity 9 $55M Abingworth
Altium Capital
Bain Capital Life Sciences
Driehaus Capital Management
Ikarian Capital
Lincoln Park Capital Fund
Monashee Investment Management
OrbiMed
Sio Capital Management
Abingworth
Altium Capital
Bain Capital Life Sciences
Driehaus Capital Management
Ikarian Capital
Lincoln Park Capital Fund
Monashee Investment Management
OrbiMed
Sio Capital Management
11/2017 Series A 1 -
1/2014 Seed Round 1 -
Announced Date Name Price
3/2019 Arsanis

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research